Characteristic | Insufficiency (n = 30) | No insufficiency (n = 55) | χ2 (t test) | P |
---|---|---|---|---|
Sex | ||||
Male | 28 | 42 | 3.846 | 0.05 |
Female | 2 | 13 | ||
HBsAg | ||||
Positive | 20 | 36 | 0.013 | 0.91 |
Negative | 10 | 19 | ||
Tumour number | ||||
Single | 18 | 34 | 0.027 | 0.869 |
Multiple | 12 | 21 | ||
Preoperative parameter | ||||
Age (year) | 43.47 ± 9.09 | 45.38 ± 12.67 | 0.731 | 0.467 |
Platelet count (109/L) | 243.08 ± 95.26 | 271.44 ± 79.10 | 1.390 | 0.171 |
Total bilirubin (μmol/l) | 16.51 ± 6.88 | 14.97 ± 13.89 | − 0.686 | 0.495 |
Albumin (g/L) | 39.62 ± 4.93 | 38.74 ± 4.26 | − 0.824 | 0.414 |
ALT (IU/L) | 49.27 ± 24.15 | 43.49 ± 27.08 | − 1.009 | 0.317 |
AST (IU/L) | 94.43 ± 84.22 | 69.29 ± 44.26 | − 1.808 | 0.074 |
Prothrombin time (s) | 13.33 ± 1.25 | 12.61 ± 1.11 | − 2.612 | 0.012* |
Alpha-foetoprotein (μg/ml) | 821.73 ± 516.56 | 742.67 ± 1267.02 | − 0.405 | 0.686 |
Body surface area (m2) | 1.99 ± 0.15 | 1.93 ± 0.17 | − 1.465 | 0.148 |
Tumour size (cm) | 12.10 ± 2.79 | 10.98 ± 4.06 | − 1.499 | 0.138 |
Remnant liver volume (ml) | 489.89 ± 177.39 | 586.16 ± 226.31 | 2.164 | 0.034* |
SRLV (ml/m2) | 238.25 ± 62.14 | 305.85 ± 103.35 | 3.762 | 0.000** |
Child–Pugh classification | ||||
A | 22 | 49 | 2.452 | 0.117 |
B | 8 | 6 | ||
Intraoperative parameter | ||||
Blood loss (ml) | 753.33 ± 623.52 | 687.27 ± 667.72 | − 0.455 | 0.651 |
Postoperative parameter | ||||
Tumour capsule | ||||
Yes | 25 | 49 | 0.174 | 0.676 |
No | 5 | 6 | ||
Macrovascular invasion | ||||
Yes | 26 | 39 | 2.679 | 0.102 |
No | 4 | 16 | ||
Hepatic fibrosis stage | 6.863 | 0.032* | ||
No significant fibrosis | 7 | 24 | ||
Severe fibrosis | 7 | 17 | ||
Cirrhosis | 16 | 14 | ||
Hospital stay (days) | 27.37 ± 7.78 | 25.51 ± 5.39 | − 1.785 | 0.069 |